Mandate

Vinge advises founder and major shareholders on the sale of Dynamic Code AB

September 17, 2021 M&A

Vinge is advising the founder and major shareholders in connection with the sale of Dynamic Code AB.

Dynamic Code develops and sells self-sampling kits based on DNA technology. The samples are analysed in Dynamic Code’s own lab and the test results are obtained through a code online. Care and treatment is thereafter offered via digital health care providers and Dynamic Code has, based on that, been able to create a complete chain of health care through its e-health platform.

Closing of the transaction is subject to due diligence and that shareholders representing 95 per cent of all shares in Dynamic Code adhere to the share transfer agreement.

The Vinge team includes Anna Edström, Magnus Hedsund and Niklas Törnell.

 

Related

Vinge advised Precise Biometrics

Vinge has advised Precise Biometrics AB in connection with the merger with Fingerprint Cards.
March 27, 2026

Vinge has advised Xspray Pharma in connection with its rights issue

Vinge has advised Xspray Pharma AB (publ) in connection with a rights issue of approximately SEK 83 million before transaction costs, with an over-allotment issue of approximately SEK 30 million.
March 26, 2026

Vinge advises Diamyd Medical in connection with directed issuances of shares and warrants of up to SEK 1,166 million

Vinge advises Diamyd Medical Aktiebolag (“Diamyd Medical”), listed on Nasdaq First North Growth Market, in connection with directed issuances of shares and warrants whereby Diamyd Medical receives gross proceeds of approximately SEK 1,166 million, if all warrants are exercised.
March 25, 2026